Advances in acute myeloid leukemia
LF Newell, RJ Cook - Bmj, 2021 - bmj.com
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …
historically high mortality rates. The standard of care treatment remained unchanged for …
Targeting macrophages in hematological malignancies: recent advances and future directions
Emerging evidence indicates that the detection and clearance of cancer cells via
phagocytosis induced by innate immune checkpoints play significant roles in tumor …
phagocytosis induced by innate immune checkpoints play significant roles in tumor …
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia
The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …
therapies entering clinical translation, yet patient responses remain heterogeneous, and …
Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease
PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
F Cichocki, R Bjordahl, S Gaidarova… - Science translational …, 2020 - science.org
The development of immunotherapeutic monoclonal antibodies targeting checkpoint
inhibitory receptors, such as programmed cell death 1 (PD-1), or their ligands, such as PD …
inhibitory receptors, such as programmed cell death 1 (PD-1), or their ligands, such as PD …
Catch me if you can: how AML and its niche escape immunotherapy
In spite of the remarkable progress in basic and preclinical studies of acute myeloid
leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the …
leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the …
Immune escape and immunotherapy of acute myeloid leukemia
L Vago, I Gojo - The Journal of clinical investigation, 2020 - Am Soc Clin Investig
In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …
Donor clonal hematopoiesis and recipient outcomes after transplantation
CJ Gibson, HT Kim, L Zhao, HM Murdock… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during
allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is …
allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is …
CAR T cells for acute myeloid leukemia: state of the art and future directions
S Mardiana, S Gill - Frontiers in oncology, 2020 - frontiersin.org
Relapse after conventional chemotherapy remains a major problem in patients with myeloid
malignancies such as acute myeloid leukemia (AML), and the major cause of death after …
malignancies such as acute myeloid leukemia (AML), and the major cause of death after …
Single-cell analysis reveals altered tumor microenvironments of relapse-and remission-associated pediatric acute myeloid leukemia
Acute myeloid leukemia (AML) microenvironment exhibits cellular and molecular differences
among various subtypes. Here, we utilize single-cell RNA sequencing (scRNA-seq) to …
among various subtypes. Here, we utilize single-cell RNA sequencing (scRNA-seq) to …